Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 3:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Interventions
docetaxel, cisplatin, 5-FU, IMRT, cetuximab, carboplatin
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Cabazitaxel 10mg/m2, Cabazitaxel 12.5mg/m2, Cabazitaxel 15mg/m2, Cabazitaxel 17.5mg/m2, Cabazitaxel 20mg/m2
Drug
Lead sponsor
Krzysztof Misiukiewicz
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma of Unknown Primary, Head and Neck Cancer, Non-melanomatous Skin Cancer
Interventions
semaxanib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions
Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Conditions
Head and Neck Cancer
Interventions
cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Kansas City, Kansas
Conditions
Advanced Solid Tumors
Interventions
ASP1948, nivolumab, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
New Haven, Connecticut • Louisville, Kentucky • Baltimore, Maryland + 13 more
Conditions
Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
Interventions
EGFR Antisense DNA
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab
Biological · Other
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more
Conditions
Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
Interventions
NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion
Drug
Lead sponsor
TyrNovo Ltd.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • San Diego, California + 4 more
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more
Conditions
Head and Neck Cancer
Interventions
gefitinib, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer, Peritoneal Cancer, Head and Neck Cancer, HNSCC, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
COTI2, Cisplatin
Drug
Lead sponsor
Critical Outcome Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions
Cisplatin, IMRT 6 weeks, IMRT 5 weeks
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
207
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 168 more
Conditions
Lymphoma, Advanced Solid Tumors
Interventions
E7766
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 1 more
Conditions
Head and Neck Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
23
States / cities
Palo Alto, California • Stanford, California • Miami, Florida + 18 more
Conditions
Head and Neck Cancer
Interventions
carboplatin, fluorouracil, hydroxyurea, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
4
States / cities
Chicago, Illinois
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Interventions
JANX008
Drug
Lead sponsor
Janux Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Duarte, California • Sacramento, California • San Diego, California + 15 more
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Interventions
PF-08046032, Sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Antonio, Texas • Seattle, Washington
Conditions
Advanced Solid Tumor, PDAC, HNSCC
Interventions
ADCE-T02
Drug
Lead sponsor
Adcendo ApS
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Rogers, Arkansas • New Haven, Connecticut • Boston, Massachusetts + 4 more
Conditions
Head and Neck Cancer
Interventions
chemotherapy, cisplatin, fluorouracil, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2013
U.S. locations
17
States / cities
Denver, Colorado • Tampa, Florida • Decatur, Georgia + 12 more
Conditions
Breast Cancer, Head and Neck Cancer
Interventions
Palbociclib, Cetuximab, Fulvestrant, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
Interventions
CAdVEC
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
1
States / cities
Houston, Texas